← All articles

Mikhail Polyakov

Stryker invested about $400 million in CMR Surgical and will sell the Versius surgical robot in the US

Level: BeginnerReading time: 4 min

Topics: Robots, Medicine

Three white robotic arms on wheeled carts above an empty operating table under a surgical lamp

The short answer: medical technology company Stryker announced an alliance with the British company CMR Surgical. Stryker, by its own account, has already invested about $400 million in it, becomes the exclusive sales agent for its Versius surgical robots in the US and gets an exclusive option to buy the whole company in the future. Outside the US, CMR continues to handle development and sales. According to The Robot Report, the deal is subject to regulatory approval and customary closing conditions; which part of it this caveat applies to is not specified in the article.

Where the news comes from

I read the article in The Robot Report (15 October 2026, bylined The Robot Report Staff). It retells the companies' statements and quotes their executives. I did not open the Stryker press release or the CMR website myself.

What the robot is

CMR Surgical is based in Cambridge, UK. According to the company, the Versius platform was designed for real operating rooms: it is assembled from modules, and this, CMR says, gives flexibility in the choice of procedures, convenient access for the surgeon and use in different healthcare facilities.

According to CMR's figures, as given by The Robot Report:

  • Versius supports procedures in general surgery, colorectal surgery, urology, gynaecology and thoracic surgery;
  • the robot has been adopted in hospitals in more than 30 countries;
  • 45,000 operations have been performed with it worldwide.

These are the company's own figures; the article contains no independent verification of them.

What is cleared in the US

This is an important caveat to the word "sell". According to The Robot Report, the Versius Plus system received FDA 510(k) clearance in the US for cholecystectomy, that is, removal of the gallbladder. The article names no other procedures cleared in the US. CMR has filed another 510(k) submission for benign gynaecological indications. The article reports no decision on it.

Terms of the deal

  • Money. According to Stryker, it has invested about $400 million in CMR Surgical.
  • US sales. Stryker becomes the exclusive commercial agent for the Versius portfolio in the US.
  • Rest of the world. CMR continues to develop products and sell them outside the US itself.
  • Acquisition. Stryker has an exclusive option to buy 100% of CMR's shares in the future on the terms of the agreement.
  • Board. CMR's chief executive said he looks forward to Andy Pierce of Stryker joining CMR's board of directors.
  • Caveat. According to The Robot Report, the deal is subject to regulatory approval and customary closing conditions.

What the companies say

CMR Surgical chief executive Massimiliano Colella called the alliance an important milestone and a recognition of the company's technology and business. In his words, Stryker's investment will help accelerate development and entry into new markets, and Stryker's scale and customer relationships open up an opportunity for growth in the US.

Andy Pierce, group president of MedSurg and Neurotechnology at Stryker, said that robotic soft tissue surgery is growing rapidly and is a natural extension of Stryker's strengths in endoscopy and imaging. In his words, the company studied this segment for years and chose CMR and Versius to help hospitals and ambulatory surgery centres use robots more widely across different procedures.

What is fact here and what is a claim

This is my breakdown, not words from the source.

  1. Deal terms. The amount of about $400 million, US sales rights, the acquisition option, the regulatory caveat.
  2. US regulatory status. FDA clearance for gallbladder removal, the article names no others; a gynaecology submission has been filed.
  3. Company claims. The number of countries and operations, the advantages of the modular design, the "rapid growth" of the segment.
  4. Unknown from the article. The price of the robot, when US sales start, the terms of a future acquisition of CMR.

How to read news like this. The word "sell" in a news story about a medical robot does not by itself tell you which procedures it is cleared for in that country. You can check this without the news story, in the FDA's public database of 510(k) clearances: on accessdata.fda.gov, the section "510(k) Premarket Notification". Search for records by applicant name (here CMR Surgical) or device name (Versius), open the record for the model you need and the document attached to it, and in it the Indications for Use section: it lists the procedures the clearance covers. Check that the model in the record is the same as in the news (here Versius Plus) and that the procedure you need is on the list. If no record is found or the procedure is not in it, that does not mean the robot is cleared for it: the question remains open, and confirmation should be requested from the manufacturer or from the treating physician.

Summary

Stryker invested about $400 million in CMR Surgical, gets exclusive rights to sell Versius robots in the US and an option to buy the company later. In the US the article names one FDA clearance for Versius Plus, for gallbladder removal, and a gynaecology submission has been filed. The figures of 30 countries and 45,000 operations come from CMR itself.

See also another piece in this section: AI in medicine: where it helps and where it fails.

I work on AI agents and automation. If you would like to see my projects or discuss your own task, take a look at my portfolio.

Sources